drug-resistant epilepsy
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: (1) Patients diagnosed with drug-resistant epilepsy as defined by ILAE 2010 (correctly selected and tolerated two anti-seizure drugs, single or combined use still cannot achieve sustained seizure free); (2) From January 2024 to January 2025 in Peking University First Hospital; (3) Age 0-18 years old; (4) Patients treated with classical ketogenic diet (classic ketogenic diet regimen); (5) Voluntarily join the study patients through informed consent.
Exclusion criteria
Exclusion criteria: (1) Clear the absolute contraindications of keto diet treatment: fatty acid metabolism disorders and biological oxidation abnormalities related diseases, such as porphyria, pyruvate carboxylase deficiency, long and medium chain 3-hydroxyacyl-coA deficiency, long and short chain acyl-dehydrogenase deficiency, carnitine deficiency (primary), carnitine palmitoyl transferase ? or ? deficiency, carnitine transtransferase deficiency; (2) Clarify the relative contraindications of ketogenic diet therapy: ketogenic diet therapy can not maintain adequate nutrition or do not cooperate with (severe malnutrition, severe vomiting and diarrhea), suitable for excision surgery (such as epileptogenic focus is clear and resectable); (3) Combined with serious cardiopulmonary and blood system diseases, liver and kidney function impairment, severe hyperlipidemia, urinary calculi or serious gastroesophageal reflux and other diseases; (4) Patients refused to join the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Responder rate of ketogenic diet at 3 months; | — |
Secondary
| Measure | Time frame |
|---|---|
| Responder rates of ketogenic diet at 6,9, and 12 months;Rates of adverse effects during ketogenic diet; | — |
Countries
China
Contacts
Peking University First Hospital